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Abstract
Muscadine grape skin extract (MSKE) is derived from muscadine grape (Vitis rotundifolia),
a common red grape used to produce red wine. Endoplasmic reticulum (ER) stress acti-
vates the unfolded protein response (UPR) that serves as a survival mechanism to relieve
ER stress and restore ER homeostasis. However, when persistent, ER stress can alter the
cytoprotective functions of the UPR to promote autophagy and cell death. Although MSKE
has been documented to induce apoptosis, it has not been linked to ER stress/UPR/autop-
hagy. We hypothesized that MSKE may induce a severe ER stress response-mediated
autophagy leading to apoptosis. As a model, we treated C4-2 prostate cancer cells with
MSKE and performed a quantitative Tandem Mass Tag Isobaric Labeling proteomic analy-
sis. ER stress response, autophagy and apoptosis were analyzed by western blot, acridine
orange and TUNEL/Annexin V staining, respectively. Quantitative proteomics analysis indi-
cated that ER stress response proteins, such as GRP78 were greatly elevated following
treatment with MSKE. The up-regulation of pro-apoptotic markers PARP, caspase-12,
cleaved caspase-3, -7, BAX and down-regulation of anti-apoptotic marker BCL2 was con-
firmed by Western blot analysis and apoptosis was visualized by increased TUNEL/
Annexin V staining upon MSKE treatment. Moreover, increased acridine orange, and LC3B
staining was detected in MSKE-treated cells, suggesting an ER stress/autophagy
response. Finally, MSKE-mediated autophagy and apoptosis was antagonized by co-treat-
ment with chloroquine, an autophagy inhibitor. Our results indicate that MSKE can elicit an
UPR that can eventually lead to apoptosis in prostate cancer cells.
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Introduction
Natural products with anticancer activities have gained increased attention due to their
favorable safety and efficacy profiles as possible therapeutic agents that are not toxic to the
surrounding healthy tissue. Of special interest is to determine how these novel compounds
affect the endoplasmic reticulum (ER), an essential organelle for proper protein folding.
Different physiological and pathological conditions can perturb protein folding in the
ER, leading to a condition known as ER stress. ER stress activates the unfolded protein
response (UPR), a complex intracellular signal transduction pathway that reestablishes ER
homeostasis through adaptive mechanisms involving the stimulation of autophagy. The
goal of the UPR is to restore optimal ER function. However, when persistent, ER stress can
switch from the cytoprotective functions of UPR and autophagy to promote cell death mech-
anisms [1].
Flavonoids from naturally rich fruits modulate cell cycles, induce apoptosis, and inhibit
extracellular regulated kinase (ERK) phosphorylation; mechanism that are linked to their
confirmed anti-carcinogenic, anti-proliferative, co-chemotherapeutic, and estrogenic effects
[2]. Numerous reports support the fact that many natural products play a positive role in
cancer prevention and treatment by adjusting the oxidative stress response, inhibiting cancer
cell proliferation and modulating apoptosis and autophagy; mechanisms that control cellular
fate by regulating the turnover of organelles and proteins [3,4]. In general, autophagy blocks
the induction of apoptosis, while apoptosis-associated caspase activation shuts off the
autophagic process. In spite of its role as a self-digestionmechanism, autophagy is mainly
activated to protect against cell death [5]. However, just like in the case of the UPR, stimula-
tion of autophagy can be required to activate the cell death machinery under certain circum-
stances [6].
Anthocyanin compounds, the main bioactive components found in muscadine grape skin
extract (MSKE) from the muscadine grape (Vitis rotundifolia), inhibit prostate cancer cell
growth and promote apoptosis in vitro without toxicity to normal prostate epithelial cells [7].
Unlike other grape varieties, the phytochemical constituents of muscadine grapes have a higher
concentration of anthocyanin 3,5-diglucosides, ellagic acid, and ellagic acid precursors [8]. In
the case of purple skinnedmuscadine grapes, the anthocyanins are primarily delphinidin-
3,5-diglucoside; cyanidin-3,5-diglucoside; and petunidin-3,5-diglucoside[8]. Anthocyanin 3,5
diglucosides are known to inhibit invasion in human hepatoma cells [9], and induce apoptosis
and inhibit invasion in colorectal cancer cells [10]. MSKE has been shown to decrease tumor
incidence, promote growth inhibition and stimulate cell death in various human cancer cell
lines [7]. It can also revert the epithelial mesenchymal transition process [11]. Furthermore,
the in vivo therapeutic effects of MSKE against prostate adenocarcinoma (PCa) are currently
being investigated in a clinical trial [12].
In this study, proteomics, Western blot, acridine orange, Annexin V and TUNEL staining
were used to determine global effects of MSKE on prostate cancer cells using C4-2 cells as a
model. Our results revealed that MSKE regulated the expression of proteins important for ER
stress response (GRP78, PDIA4, PDIA6, EIF2, EIF4 and Ire-1 alpha) and autophagy (ACIN1,
PI4KA, PGK2 and MTDH). Pro-apoptotic markers were up-regulated, while anti-apoptotic
protein BCL2was down-regulated in the presence of MSKE; these effects were antagonized by
co-treatment with chloroquine, suggesting that MSKEmay promote ER stress-driven autopha-
gic response leading to apoptosis.
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Materials and Methods
Cell Culture, Reagents and Antibodies
C4-2 human prostate cells were grown in RPMI (Lonza, Alpharetta, GA) supplemented with
10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA) and 1 × penicillin-strepto-
mycin solution (Mediatech, Manassas, VA) at 37°C in a humidified incubator with 5% CO2.
MSKE, which is composedmainly of anthocyanins, was prepared as previously described [7].
The protease inhibitor cocktail was purchased from RocheMolecular Biochemicals (Indianap-
olis, IN) and used according to the manufacturer’s instructions. Chloroquine (autophagy
inhibitor) was purchased from Sigma Aldridge.(St. Louis,MO). Annexin V/cell death apoptosis
kit was purchased from Thermo Fisher Scientific (Waltham, MA).
Gel-free Isobaric Labeling Tandem Mass Tag Quantitative Proteomic
Profiling of C4-2 Cells Treated with MSKE
Cell lysis and protein extraction. Cells were plated on 150 cm2 culture plates at a cell den-
sity of 5 × 106 and treated the following day with 20 μg/mlMSKE for 72 h. Cells treated with
0.1% ethanol were used as controls. Proteins were extracted with RIPA buffer (1.5 M Tris pH
8.8, 1.75 g NaCl, 2 mL sodiumdodecyl sulfate 10%, 2 mL Triton X-100; all reagents from
Thermo Fisher Scientific,Waltham, MA). The cells were incubated on ice for 30 min, followed
by 5 min sonication and centrifugation at 20,000 rpm for 5 min in preparation for protein
extraction. Protein concentration was calculated on microtiter plates by measuring the absor-
bance at 595 nm of samples containing a commercial protein assay (Bio-Rad Laboratories,
Hercules, CA) supplemented with 10 μL of phosphatase inhibitor cocktail and 10 μL of prote-
ase inhibitor cocktail (RocheMolecular Biochemicals, Indianapolis, IN).
Reduction, alkylation, and trypsindigestion. Aliquots with 100 mg of proteins from
each sample were added to 100 ml of 200 mM triethyl ammonium bicarbonate TEAB (Sigma-
Aldrich, St. Louis, MO). Reductionwas performed by adding 5 ml of 200 mM tris (2-carbox-
yethyl) phosphine TCEP (Sigma-Aldrich, St. Louis,MO) to each replicate and incubating for 1
h at 55°C. Alkylation was carried out by adding 5 ml of 375 mM iodoacetamide (Bio-Rad Labo-
ratories, Hercules, CA) to each sample and incubating for 30 min at room temperature. After
alkylation, 1 ml of pre-chilled acetone was added and precipitation was allowed to proceed for
3 h at 20°C. Acetone-precipitated protein pellets were suspended in 100 ml of 200 mM TEAB
and digested overnight at 37°C with 2.5 μg of sequencing grademodified trypsin (Promega
Corp., Madison, WI) as previously described [13,14].
Isobaric Labeling with Tandem Mass Tag
Tandem mass tag TMT with varyingmolecular weights (126 ~ 131) (Thermo Scientifc,Wal-
tham, MA) were applied as isobaric labels for the comparison of differential protein expression
betweenC4-2 cells treated with ethanol (0.1%) and C4-2 treated with 20 μg/mlMSKE. Six
digested samples were individually labeled with TMT6 reagents according to the manufactur-
er’s protocols. Three control (ethanol-treated) samples: TMT-126 (batch 1), TMT-127 (batch
2), and TMT-128 (batch3); and threeMSKE-treated samples: TMT-129 (batch 1), TMT-130
(batch 2), and TMT-131 (batch3) were used in the studies. The labeled peptidemixtures were
combined at equal ratios.
Fractionation of labeledpeptidemixture by using a strong cation exchange column.
The TMT-labeled peptidemixture was fractionated with a strong cation exchange SCX column
(Thermo Fisher Scientific,Waltham, MA) on a Shimadzu 2010 high performance liquid chro-
matography (HPLC) equipped with an ultraviolet detector (Shimadzu, Columbia, MD) and a
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mobile phase consisting of buffer A (5 mMKH2PO4, 25% acetonitrile, pH 2.8) and buffer B
(buffer A plus 350 mMKCl). The column was equilibrated with buffer A for 30 min before
sample injection. A mobile phase gradient at a flow rate of 1.0 ml/min was set as follows: 1)
0 ~ 10 min: 0% buffer B; 2) 10 ~ 40 min: 0 ~ 25% buffer B; 3) 40 ~ 45 min: 25 ~ 100% buffer B;
4) 45 ~ 50 min: 100% buffer B; 5) 50 ~ 60 min: 100 ~ 0% buffer B; and 6) 60 ~ 90 min: 0%
buffer B. Sixty fractions were initially collected, lyophilized, and combined into 10 final frac-
tions based on SCX chromatogram peaks.
Desalination of fractionated samples. A C18 solid phase extraction SPE column (Thermo
Fisher Scientific,Waltham, MA) was used to desalt all collected fractions as previously
described [15]. Briefly, the 10 combined fractions were each adjusted to a final volume of 1 ml
in a 0.25% trifluoroacetic acid TFA aqueous solution. The C18 SPE column was preconditioned
with 1 ml acetonitrile and eluted in approximately 3 min before it was rinsed with 3 × 1 ml
0.25% TFA. The fractions were loaded on to the top of the SPE cartridge column slowly, and
were reloaded once again to decrease lost peptide during column binding. Columns were
washed with 4 × 1 ml 0.25% TFA aliquots before the peptides were eluted with 3 × 400 μl 80%
acetonitrile/0.1% formic acid (aqueous). The eluted samples were lyophilized prior to the liquid
chromatography mass spectrometryLC-MS/MS analysis.
LC-MS/MS analysis. Peptides were analyzed on an LTQ-Orbitrap XL (Thermo Fisher Sci-
entific,Waltham, MA) instrument interfaced with an Ultimate 3000 Dionex LC system (Dio-
nex, Sunnyvale, CA). High mass resolution was utilized for peptide identification and high-
energy collision dissociation (HCD) was used for reporter ion quantification as previously
described [15]. Briefly, the reverse phase LC system contained a peptide Cap-Trap cartridge
(0.5 × 2 mm) (Michrom BioResources, Auburn, CA) and a pre-packed BioBasic C18 PicoFrit
analytical column (75 μm i.d. × 15 cm length, New Objective,Woburn, MA) fitted with a For-
tisTip emitter tip. Samples were loaded onto the trap cartridge and washed with mobile phase
A (98% H2O, 2% acetonitrile, and 0.1% formic acid) for concentration and desalting. Peptides
were eluted over 180 min from the analytical column via the trap cartridge by using a linear
gradient of 6 to 100%mobile phase B (20% H2O, 80% acetonitrile, and 0.1% formic acid) at a
flow rate of 0.3 μl/min.
The Orbitrap mass spectrometer was operated in a data-dependent mode in which each full
MS scan (60,000 resolving power) was followed by six MS/MS scans where the three most
abundant molecular ions were dynamically selected and fragmented by collision-induceddis-
sociation with a normalized collision energy of 35% and subsequently scanned by HCD-MS2
with a collision energy of 45% as previously described [15]. Only the 2+, 3+, and 4+ ions were
selected for fragmentation by collision-induceddissociation and HCD.
Database Search and TMT Quantification
The protein search algorithm SEQUEST was used to identify unique protein peptides using the
Proteome Discoverer data processing software (version 1.2, Thermo Fisher Scientific,Wal-
tham, MA). The ratios of TMT reporter ion abundances in MS/MS spectra generated by HCD
from raw data sets were used For TMT quantification. Fold changes in proteins between con-
trol and treatment were calculated as previously described [15].
Western Blot
20–30 μg of proteins extractedwith RIPA buffer were analyzed by SDS PAGE and transferred
to a nitrocellulosemembrane. Membranes were blocked with 5% non-fat drymilk in 1 × TBST
buffer (BioRad, Hercules, CA) and incubated with primary antibodies overnight at 4°C. The
following primary antibodies were used at a 1:1000 dilution LC3B, cleaved caspase-3, cleaved
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caspase-7, BAX, and BCL2 (Cell Signaling Technologies Danvers, MA.), anti-caspase-12, Ire-
1α, GRP78, DFF45, and PARP (Abcam, Cambridge,MA). Anti-β-actin (1:500, Sigma-Aldrich,
St. Louis, MO) were used as a loading control. Horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (Sigma Aldrich, St Louis, MO) were used and protein bands were visualized
by a chemiluminescencemethod using the SuperSignalWest Femto Maximum Sensitivity Sub-
strate kit (Thermo Fisher Scientific,Waltham, MA). Images were analyzed with the ImageJ
image processing program version 1.50b (National Institutes of Health, Bethesda,MD) to
access the differential expression of key ER stress and apoptotic markers.
Analysis of Autophagy
Acridine Orange (AO) was used to analyze autophagy. Briefly, 5 × 103 cells were plated into
Nunc 8-well chamber slides (Bio-Tek Instruments, Winooski, VT). Cells were serum-starved
for 4 h and treated with increasing concentrations (0 μg/mL, 5 μg/mL, 10 μg/mL or 20 μg/mL)
of MSKE for 72 h. Fixation was performedwith methanol/ethanol (1:1 volume) for 5 min, fol-
lowed by washes with 1 × PBS. Cells were exposed to 5 μg/ml AO for 15 min at 37°C, washed
with 1 × PBS, and counterstained with 1 μg/ml DAPI (Santa Cruz Biotechnology, Santa Cruz,
CA) before they were fixed with Fluorogel mounting medium (ElectronMicroscopy Sciences,
Hatfield, PA). Co-treatments with the autophagy inhibitor (20 μM chloroquine) for 72 h was
also performed. Fluorescencemicroscopy was performed at 40 × oil magnification on a Zeiss
fluorescencemicroscope equipped with the AxioVision (release 4.8) imaging software and the
ApoTome.2 optical sections system (Carl ZeissMicroscopy GmbH, Jenna, Germany).
Immunofluoresence for LC3B
5 × 103 cells were plated into Nunc 8-well chamber slides (Bio-Tek Instruments, Winooski,
VT). Cells were serum-starved for 4 h and treated with 0 μg/mL or 20 μg/mL of MSKE with or
without 20 μM chloroquine co-treatment for 72 h. Fixation was performedwith methanol/eth-
anol (1:1 volume) for 5 min, followed by washes with 1 × PBS. Subsequently, slides were incu-
bated with primary antibody (LC3B) at 1:50dilution in Dako antibody diluent solution for 1 h
at room temp. Slides were washed with 1× TBS-T (Dako, Camarillo, CA), then incubated with
secondary antibody in the dark for 1 h at room temp. Anti-rabbit Oregon green 488 was uti-
lized as a secondary, and slides were then counterstained with 1 μg/ml DAPI (Santa Cruz Bio-
technology, Santa Cruz, CA) before they were fixed with Fluorogel mounting medium
(ElectronMicroscopy Sciences,Hatfield, PA). Fluorescencemicroscopy was performed at
40 × oil magnification on a Zeiss fluorescencemicroscope equipped with the AxioVision
(release 4.8) imaging software and the ApoTome.2 optical sections system (Carl ZeissMicros-
copy GmbH, Jenna, Germany).
TUNEL Assay
The terminal deoxynucleotidyl transferase (TdT) dUTP nick-end tabeling (TUNEL) assay was
used to detect apoptosis. Briefly, 5 × 103 cells were plated into 16-well Nunc chamber slides
(Bio-Tek, Winooski, VT). Cells were serum starved for 4 h and treated with increasing concen-
trations of MSKE (0 μg/mL, 5 μg/mL, 10 μg/mL or 20 μg/mL) for 72 h. The cells were fixed
with 4% paraformaldehyde and permeabilizedwith 0.1% sodium citrate and 0.1% Triton X-
100. DNA fragmentation was determined by TUNEL according to the manufacturer’s instruc-
tions (Roche Applied Science, Penzberg, Germany) prior to counterstaining with 1 μg/ml
DAPI (Santa Cruz Biotechnology, Santa Cruz, CA). Slides were mounted with Fluorogel
mounting medium (ElectronMicroscopy Sciences,Hatfield, PA) and visualized under 40 × oil
magnification on a Zeiss fluorescencemicroscope equipped with the AxioVision (release 4.8)
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imaging software and the ApoTome.2 optical sections system (Carl ZeissMicroscopy GmbH,
Jenna, Germany).
Annexin V/Cell Death Apoptosis Kit
Annexin V was also used to detect apoptosis. Briefly C4-2 Cells were serum starved for 4 h and
treated with different concentrations of MSKE (0 μg/mL, 5 μg/mL) for 72 h, with or without
20 μM chloroquine. Apoptosis was assessed by Alexa Fluor 488 Annexin V and propidium
iodide double staining and flow cytometrywas performed using Accuri C6 Flow Cytometer
(Accuri Cytometers Inc., Ann Arbor, MI.) according to the manufacterer instructions. Cells
that stained positive for Annexin V- Alexa Fluor 488 and negative for PI (Alexa Fluor 488+/
PI-) were considered to be undergoing early apoptosis; Alexa Fluor 488+/PI+ were considered
as late apoptosis; Alexa Fluor 488-/PI- considered non-apoptotic (viable). Experiments were
performed in triplicate in two independent experiments, and a representative result displayed
in the form of early/late apoptosis graphs.
Statistical Analysis
Cytotoxicity assays and proteomics analyses were performed in triplicate, and similar results
were obtained on at least three separate studies. Statistical analysis was performed using paired
or unpaired t-tests, as appropriate, using the GraphPad PRISM v6.03 statistical software
(GraphPad Software, La Jolla, CA). A p value of 0.05 was considered statistically significant
and all data are presented as means ± standard error and range.
Results
Proteomic Profiling of C4-2 Cells Treated with MSKE with a Gel-Free
Isobaric Labeling TMT Quantitative Proteomic Approach
The differential expression of proteins between untreated (0.1% ethanol) and treated (20 μg/ml
MSKE) C4-2 cells was determined based on a gel-free isobaric labeling TMT quantitative
proteomic approach for further validation and identification of novel proteins. Over 1,855 pro-
teins were identified from control and treated C4-2 cell lysates. Among them, 465 significantly
differentially expressed proteins contained TMT signals that were used to determine protein
expression ratios between treated and control C4-2 cells. Proteins up-regulated or down-regu-
lated at least 1.2 fold were organized according to biological processes (Fig 1). The detailed
information including protein ID, gene name, number of amino acids, molecular weight, calcu-
lated pI, description, coverage samples, protein expression, change folds, and p-values are
shown in S1 Table. Proteins that had a fold change of at least 1.2 and p-values 0.05 were
closely examined and are listed in Table 1. MSKE-treated C4-2 cells expressed 254 up-regulated
and 211 down-regulated proteins when compared to C4-2 control cells.
Among the proteins that were differentially expressed, ER stress markers, such as 78 kDa
glucose-regulatedprotein (GRP78) and protein disulfide isomerase A4 and A6 (PDIA4,
PDIA6), as well as oxidative stress markers sulfiredoxin (SRXN1) and ubiquinone (NDUFS1
and NDUFS3) were up-regulated. Additional ER stress-related proteins identified among the
up-regulations are eukaryotic translation initiation factor 2B (eIF2B) and eukaryotic transla-
tion initiation factor 4 binding protein (eIF4EBP1) with a respective significant fold change of
1.5 and 1.3 and the protein disulfide isomerase (PDI) A4 and A6 with a differential expression
of 1.21 and 1.26, respectively. Key differentially expressed proteins induced by MSKE in C4-2
cells included those associated with apoptosis (e.g., STEAP2, PDCD6,MTDH, RAB5B, cyto-
chrome c oxidase), autophagy (e.g., ACIN1, PI4KA, PGK2, MTDH), cytoskeleton and protein
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transport (e.g., cortactin, taxilin, radixin, filamin B), among others (Table 1). Furthermore, C4-
2 control cells had a higher percent of anti-apoptotic proteins compared to the MSKE-treated
cells, suggesting that MSKE induces an ER stress/autophagy/apoptosis signature.
MSKE Induces Expression of ER Stress Mediated Pro-Apoptotic
Response Proteins
Western blot was used to measure the expression of proteins associated with ER stress
response. Key ER stress response markers IRE-1 alpha and GRP78 (Fig 2) were up-regulated
when compared to control cells. Apoptotic markers PARP, caspase-12 and DFF45 (Fig 2) were
up-regulated in cells exposed to MSKE. These data suggest that MSKEmay induce ER stress
and UPR-mediated apoptosis.
MSKE Treatment Induces Autophagy
SinceMSKE induced expression of ER stress response proteins, we sought to determine if
treatment with MSKE induces autophagy. We treated C4-2 cells with 5, 10 or 20 μg/mlMSKE
for 72 h and stained with acridine orange. Treatment with higher concentrations of MSKE
(10 and 20 μg/mL) showed extensive acridine orange leakage into the cytosol (orange staining),
indicating that MSKE induces autophagy (Fig 3A). Since the 20 μg/mLMSKE treatment
showed extensive acridine orange staining we decided to see if co-treatment with chloroquine,
a known autophagy inhibitor would reverse the effects of MSKE on C4-2 cells. Co-treatment
with 20 μg/mLMSKE and 20 μM chloroquine lead to a decrease in acridine orange staining
compared to 20 μg/mLMSKE alone, indicating that MSKEmay promote autophagy (Fig 3B).
To further validate a role for MSKE in autophagy, we also performed immunofluorescence and
western blot with the autophagic marker, LC3B. There was increased punctate staining for
Fig 1. TMT labeled proteins identified by MS and organized according to biological processes. Fig 1 shows proteins
up-regulated or down-regulated at least 1.2 fold in C4-2 cells treated with 20 μg/ml MSKE as identified by the MASCOT
database.
doi:10.1371/journal.pone.0164115.g001
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Table 1. Differentially expressed proteins in MSKE-treated and control cultures.







Peptidyl-prolyl cis-trans isomerase F, mitochondrial 85.79 2.63417E-09 PPIF 21.26 1.23 22.03 9.38
Aldo-keto reductase family 1 member C1 20.02 0.009954054 AKR1C1 5.45 1.88 24.94 7.49
PAX3- and PAX7-binding protein 1 31.82 0.000657658 PAXBP1 3.13 -1.43 57.40 5.25
*annexin A4 220.76 8.39334E-23 ANXA4 20.87 -1.20 36.06 6.13
Rho guanine nucleotide exchange factor (GEF) 16 97.39 1.82266E-10 ARHGEF16 12.33 -1.29 17.10 6.13
BCL2-associated transcription factor 1 30.77 0.000837529 BCLAF1 3.64 -1.23 52.89 11.22
Cyclin-dependent kinase 5 31.84 0.000654636 CDK5 5.48 -1.20 33.28 7.66
ARL-6-interacting protein 1 647.58 1.7459E-65 CG10326 18.54 1.32 17.15 7.96
*Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 57.86 1.63682E-06 COX4I1 13.02 1.28 19.56 9.51
*Cytochrome c oxidase subunit 7A2, mitochondrial 107.11 1.94405E-11 COX7A2 15.66 1.23 9.39 9.76
casein kinase 2, alpha 1 polypeptide 103.29 4.68943E-11 CSNK2A1 11.95 -1.20 45.28 7.94
*Catenin delta-1 818.43 1.43523E-82 CTNND1 19.21 -1.29 90.34 7.03
Drebrin-like protein 45.33 2.93089E-05 DBNL 3.4 -1.20 43.01 5.03
Diablo homolog, mitochondrial 29.52 0.001116863 DIABLO 37.66 1.46 8.84 5.01
Dynein light chain 2, cytoplasmic 163.12 4.87128E-17 DYNLL2 32.58 -1.23 10.34 7.37
elongation factor 1-delta isoform 4 734.76 3.34299E-74 EEF1D 36.19 1.29 28.54 4.92
Glutamate-cysteine ligase, modifier subunit, isoform CRA_a 140.93 8.07457E-15 GCLM 18.5 1.32 28.60 6.02
Growth/differentiation factor 15 188.91 1.28552E-19 GDF15 14.29 1.32 34.12 9.66
*Lactoylglutathione lyase 795.53 2.79874E-80 GLO1 55.62 -1.20 19.03 6.05
Golgi phosphoprotein 3 61.95 6.37832E-07 GOLPH3 12.85 -1.24 32.91 6.71
High mobility group protein B1 757.12 1.9406E-76 HMGB1 39.53 -1.27 24.88 5.74
lamin-B1 isoform 2 55.31 2.94217E-06 LMNB1 2.66 1.24 43.00 5.12
mitogen-activated protein kinase 3 106.76 2.10863E-11 MAPK3 9.68 -1.22 17.92 8.70
Macrophage migration inhibitory factor 316.04 2.48889E-32 MIF 55.65 -1.26 12.47 7.88
Cytochrome c oxidase subunit 2 40.84 8.24138E-05 MT-CO2 4.41 1.44 25.55 4.82
NEDD8-activating enzyme E1 regulatory subunit isoform c 86.98 2.00638E-09 NAE1 5.17 1.27 50.59 5.27
occludin 78.58 1.38788E-08 OCLN 10.5 -1.64 23.31 6.06
*Programmed cell death protein 6 428.90 1.28687E-43 PDCD6 9.63 1.31 15.57 8.19
Prohibitin 1313.07 4.9365E-132 PHB 64.34 1.23 29.79 5.76
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 28.56 0.001393157 PIN1 9.2 -1.60 18.23 8.82
Protein kinase C delta type 88.67 1.35752E-09 PRKCD 6.51 -1.35 77.45 7.75
Phosphoserine aminotransferase 1228.55 1.397E-123 PSAT1 48.67 1.26 45.33 9.03
Tyrosine-protein phosphatase non-receptor type6 73.96 4.01791E-08 PTPN6 3.43 -1.20 66.19 7.23
*Ras-related protein Rab-21 116.33 2.32652E-12 RAB21 4.89 1.20 24.33 7.94
*Ras-related protein Rab-5A 157.52 1.76979E-16 RAB5A 12.44 1.27 22.16 8.82
*Ras-related protein Rab-5B 220.12 9.73258E-23 RAB5B 17.21 1.27 23.69 8.13
*Ras-related C3 botulinum toxin substrate 1 66.40 2.29241E-07 RAC1 11.98 1.22 21.44 8.50
Sigma non-opioid intracellular receptor 1 32.66 0.000542001 SIGMAR1 6.42 -1.21 21.00 5.45
Guanine nucleotide exchange factor VAV2 25.09 0.00309803 VAV2 1.91 -1.27 96.97 6.90
glycogen synthase kinase 3 beta 37.06 0.000196789 GSK3B 20.19 -1.25 11.56 8.02
AUTOPHAGY
*apoptotic chromatin condensation inducer in the nucleus isoform 3 124.92 3.21851E-13 ACIN1 3.23 -1.60 147.30 6.73
*Protein LYRIC 25.49 0.00282488 MTDH 3.04 1.91 57.49 9.54
*Phosphoglycerate kinase 2 651.02 7.91169E-66 PGK2 20.14 -1.22 44.77 8.54
*Phosphatidylinositol 4-kinase alpha 27.37 0.001832314 PI4KA 0.93 1.19 231.17 6.87
Ubiquilin-4 29.37 0.001156112 UBQLN4 5.49 1.44 63.81 5.22
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ADP-ribosylation factor-like protein 8A 72.86 5.17257E-08 ARL8A 9.14 -1.37 21.40 7.77
BolA-like protein 2 150.26 9.41588E-16 BOLA2 23.03 -1.28 16.92 8.19
Calcium-binding protein 39 62.81 5.24105E-07 CAB39 6.16 -2.43 39.84 6.89
DEAD (Asp-Glu-Ala-Asp) box helicase 5 197.54 1.76228E-20 DDX5 18.82 -1.24 51.70 9.03
Deoxyribonucleoside 5’-monophosphate N-glycosidase 160.14 9.68456E-17 DNPH1 29.31 1.30 19.10 5.05
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 118.28 1.48531E-12 GSPT1 6.01 1.20 55.72 5.62
Nucleolar GTP-binding protein 1 33.06 0.000494311 GTPBP4 2.12 -1.23 60.01 9.39
*HEAT SHOCK FACTOR PROTEIN 1 81.23 7.53356E-09 HSF1 5.25 -1.46 31.92 5.38
Ragulator complex protein LAMTOR2 28.86 0.00130017 LAMTOR2 14.4 1.60 13.50 5.40
*minichromosome maintenance complex component 2 146.21 2.39378E-15 MCM2 6.81 -1.56 91.22 6.43
DNA replication licensing factor MCM3 317.45 1.79731E-32 MCM3 13.78 -1.25 85.59 6.15
DNA replication licensing factor MCM4 82.29 5.90347E-09 MCM4 4.86 -1.55 92.66 6.98
minichromosome maintenance complex component 5 184.10 3.8897E-19 MCM5 8.68 -1.51 77.54 8.60
DNA replication licensing factor MCM6 95.87 2.58985E-10 MCM6 36.14 -1.63 9.53 4.41
MCM7 isoform 2 65.31 2.94243E-07 MCM7 4.24 -1.28 60.60 6.25
N-myc downstream regulated 1 559.73 1.06484E-56 NDRG1 20.37 -1.37 35.27 6.34
Nucleolar and coiled-body phosphoprotein 1 262.61 5.48094E-27 NOLC1 11.44 1.24 73.56 9.47
protein phosphatase, Mg2+/Mn2+ dependent, 1G 333.88 4.09025E-34 PPM1G 7.75 -1.23 57.31 4.34
protein phosphatase 1 regulatory subunit 12A isoform b 148.47 1.42272E-15 PPP1R12A 3.5 1.61 105.58 5.38
protein phosphatase 1, regulatory subunit 8 85.59 2.76058E-09 PPP1R8 10.24 -1.49 22.27 5.92
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B
alpha isoform
372.95 5.06492E-38 PPP2R2A 13.42 -1.24 51.66 6.20
Delta-3 of Serine/threonine-protein phosphatase 2A 56 kDa regulatory
subunit delta
41.00 7.94328E-05 PPP2R5D 2.42 1.52 58.42 6.77
protein phosphatase 3, regulatory subunit B, alpha 50.17 9.61612E-06 PPP3R1 11.25 -1.35 18.20 4.92
protein kinase, AMP-activated, gamma 1 non-catalytic subunit 61.42 7.2062E-07 PRKAG1 7.69 -1.28 28.27 7.02
spindle pole body component 24 homolog (SPBC24), mRNA 40.85 8.22243E-05 SPC24 11.26 -1.24 17.30 4.93
Testin 32.01 0.000629506 TES 5.59 1.59 20.64 6.48
*E3 ubiquitin-protein ligase UBR5 120.37 9.17712E-13 UBR5 1.5 1.21 308.38 5.85
ZW10 protein 55.91 2.56448E-06 ZW10 2.98 1.36 76.76 6.32
CYTOSKELETAL
Neuroblast differentiation-associated protein AHNAK 254.32 3.7017E-26 AHNAK 10.05 -1.24 628.70 6.15
actin-related protein 2/3 complex subunit 4 isoform b 27.12 0.001940886 ARPC4 10.26 -1.21 9.55 7.52
Actin-related protein 2/3 complex subunit 5 42.98 5.03501E-05 ARPC5 9.63 1.37 14.80 5.06
CCDC88A protein 61.95 6.37733E-07 CCDC88A 0.33 1.21 207.67 5.97
Calicin 27.87 0.001633052 CCIN 2.38 -3.15 66.54 8.18
Cytoskeleton-associated protein 5 40.21 9.52796E-05 CKAP5 4.93 1.32 22.74 8.05
CLIP-associating protein 2 105.22 3.00771E-11 CLASP2 1.81 1.31 138.78 8.34
claudin domain-containing protein 1 isoform b 28.75 0.001333521 CLDND1 5.07 1.43 31.03 6.11
Protein cordon-bleu 22.69 0.005382698 COBL 0.55 1.61 136.60 8.07
*cortactin 28.61 0.001377209 CTTN 9.81 1.69 29.60 4.91
DmX-like protein 2 24.41 0.003622 DMXL2 0.2 -1.36 339.43 6.38
DnaJ homolog subfamily B member 6 35.27 0.000297167 DNAJB6 19.7 1.25 7.88 7.40
Niban-like protein 1 147.68 1.7054E-15 FAM129B 5.73 -1.22 82.63 6.15
Filamin-B 2200.56 8.788E-221 FLNB 20.64 -1.22 275.50 5.78
Huntingtin-interacting protein K 59.27 1.18304E-06 HYPK 11.63 -1.57 14.66 4.93
Intraflagellar transport protein 27 homolog 36.74 0.000211836 IFT27 6.2 2.31 14.02 4.64
Junction plakoglobin 400.46 8.9848E-41 JUP 14.63 -1.24 81.69 6.14
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Kinesin-like protein 26.05 0.002483133 KIF3C 0.89 1.91 75.75 7.15
Kinesin light chain 2 23.07 0.004931738 KLC2 1.15 1.25 57.14 8.21
Keratin, type II cytoskeletal 8 3479.34 0 KRT8 62.32 -1.27 53.67 5.59
LIM domain and actin-binding protein 1 44.21 3.79315E-05 LIMA1 3.09 1.48 43.16 8.51
macrophage erythroblast attacher 49.94 1.01391E-05 MAEA 19.63 -1.28 11.83 8.00
Microtubule-associated proteins 1A/1B light chain 3 beta 2 32.17 0.000606736 MAP1LC3B2 11.2 1.68 14.62 8.68
palmitoylated 5 (MAGUK p55 subfamily member 5) 72.66 5.42001E-08 MPP5 8.05 -1.26 17.18 6.70
Protein PRRC1 161.42 7.21439E-17 PRRC1 6.97 1.22 46.67 5.83
Radixin 176.11 2.44856E-18 RDX 7.89 1.30 68.52 6.37
Ras-related protein R-Ras 117.96 1.59848E-12 RRAS 12.84 -1.25 23.47 6.93
Na+/H+ exchange regulatory co-factor (NHERF) mRNA 98.76 1.32928E-10 SLC9A3R1 14.65 -1.42 29.42 6.80
spectrin, beta, non-erythrocytic 2 35.29 0.000295801 SPTBN2 1.61 -1.48 105.60 7.75
tubulin, beta 6 class V 1231.71 6.7485E-124 TUBB6 55.67 -1.22 44.57 4.93
*Alpha-taxilin 32.11 0.000615177 TXLNA 2.56 1.37 61.85 6.52
ER STRESS
Cystathionine gamma-lyase 306.48 2.24785E-31 CTH 13.3 1.47 39.48 6.90
*Translation initiation factor eIF-2B subunit alpha 33.77 0.000419759 EIF2B1 4.61 1.51 16.92 6.90
Protein Niban 67.07 1.96515E-07 FAM129A 3.02 1.44 103.07 4.78
Mesencephalic astrocyte-derived neurotrophic factor 139.84 1.03761E-14 MANF 25.27 1.29 20.69 8.69
B-cell receptor-associated protein 31 389.58 1.10175E-39 BCAP31 22.36 1.21 27.97 8.44
*Eukaryotic translation initiation factor 4E-binding protein 1 124.81 3.30025E-13 EIF4EBP1 15.25 1.28 12.57 5.48
Endoplasmic reticulum resident protein 29 364.95 3.20115E-37 ERP29 26.05 1.30 28.98 7.31
Endoplasmin 6243.82 0 HSP90B1 52.93 1.30 92.41 4.84
*78 kDa glucose-regulated protein 7582.64 0 HSPA5 60.24 1.67 72.29 5.16
*60 kDa heat shock protein, mitochondrial 19539.31 0 HSPD1 82.02 1.23 61.02 5.87
Protein disulfide-isomerase 1239.55 1.1085E-124 P4HB 49.46 1.38 32.13 8.51
Protein disulfide-isomerase 3026.26 2.3635E-303 P4HB 58.07 1.37 57.08 4.87
*Protein disulfide-isomerase A4 3139.65 0 PDIA4 53.18 1.21 72.89 5.07
*Protein disulfide-isomerase A6 1106.04 2.4891E-111 PDIA6 31.35 1.26 47.81 5.08
*Thioredoxin-related transmembrane protein 2 30.71 0.00084918 TMX2 10.47 1.22 29.62 8.65
E3 UFM1-protein ligase 1 42.96 5.05825E-05 UFL1 3.93 1.20 57.55 6.30
endoplasmic reticulum-resident ubiquitin-like domain member 1 protein
(Fragment)
59.25 1.1885E-06 HERPUD1 8.19 1.37 26.20 5.77
GENE EXPRESSION
acidic leucine-rich nuclear phosphoprotein 32 family member E isoform 3 313.17 4.81956E-32 ANP32E 22.27 -1.43 25.11 3.74
Ataxin-2-like protein 434.72 3.37392E-44 ATXN2L 1.14 1.54 102.83 8.63
Barrier-to-autointegration factor 382.78 5.27164E-39 BANF1 40.45 -1.36 10.05 6.09
C5orf38 protein 34.05 0.000393587 C5orf38 8.15 1.33 14.68 11.27
chromobox homolog 1 157.35 1.8397E-16 CBX1 24.4 -1.22 19.31 5.02
CD81 molecule 122.31 5.88048E-13 CD81 21.51 -1.24 10.09 4.59
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2,
mitochondrial
45.54 2.79254E-05 CHCHD2 11.26 1.52 15.50 9.22
UMP-CMP kinase isoform a 632.76 5.29998E-64 CMPK1 25 -1.22 25.84 7.97
Cleavage and polyadenylation specificity factor subunit 7 48.60 1.37945E-05 CPSF7 10.55 1.32 26.13 9.51
Probable ATP-dependent RNA helicase DDX6 89.47 1.13097E-09 DDX6 8.28 1.24 54.38 8.66
Enhancer of mRNA-decapping protein 4 349.20 1.20135E-35 EDC4 11.86 -1.25 109.66 5.99
Elongation factor 1-beta 352.91 5.11228E-36 EEF1B2 44.89 1.20 24.75 4.67
Zinc phosphodiesterase ELAC protein 2 37.70 0.000169824 ELAC2 3.79 -1.20 56.06 7.43
EWS RNA-binding protein 1 149.95 1.01187E-15 EWSR1 9.42 -1.36 32.16 9.82
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G-rich sequence factor 1 isoform 2 68.69 1.35317E-07 GRSF1 6.92 -1.34 36.59 5.69
general transcription factor IIA, 1, 19/37kDa 76.72 2.12814E-08 GTF2A1 18.64 -1.60 6.74 4.72
General transcription factor IIF subunit 2 59.04 1.24847E-06 GTF2F2 5.22 -1.28 28.36 9.23
histone H2A.V isoform 2 969.32 1.16911E-97 H2AFV 16.67 1.44 12.14 10.46
Heterogeneous nuclear ribonucleoprotein A/B 289.20 1.20359E-29 HNRNPAB 17.86 1.25 30.28 7.91
heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA
binding protein 1, 37kDa)
555.96 2.53589E-56 HNRNPD 50.89 -2.18 12.63 8.57
insulin-like growth factor 2 mRNA binding protein 3 28.17 0.001524053 IGF2BP3 12.35 -1.20 8.89 5.78
La ribonucleoprotein domain family, member 7 58.03 1.57398E-06 LARP7 7.19 -1.43 38.18 9.32
39S ribosomal protein L12, mitochondrial 188.09 1.5512E-19 MRPL12 29.29 1.47 21.33 8.87
myb-related protein A isoform 2 28.34 0.001465548 MYBL1 1.45 1.30 78.90 6.68
Myosin Ic 575.17 3.03883E-58 MYO1C 15.53 -1.25 92.27 8.87
nuclear cap binding protein subunit 1, 80kDa 34.35 0.000367282 NCBP1 29.27 -1.30 9.18 6.77
NELF-D of Negative elongation factor C/D 34.11 0.00038815 NELFCD 1.72 -1.88 65.44 5.10
Cleavage and polyadenylation specificity factor subunit 5 63.27 4.70977E-07 NUDT21 27.31 -1.33 26.21 8.82
Phosphorylated adapter RNA export protein 29.12 0.001224616 PHAX 2.79 -1.25 44.38 5.40
phosphatidylinositol-binding clathrin assembly protein isoform 4 133.72 4.24178E-14 PICALM 8.53 -1.26 59.88 8.76
Pentatricopeptide repeat-containing protein 3, mitochondrial 86.22 2.3862E-09 PTCD3 7.69 1.28 78.50 6.42
Putative peptidyl-tRNA hydrolase PTRHD1 33.65 0.000431519 PTRHD1 17.86 -1.26 15.80 9.10
retinoblastoma binding protein 7 33.52 0.000444631 RBBP7 7.69 -1.33 46.91 5.07
RNA-binding protein 10 isoform 5 53.58 4.38531E-06 RBM10 3.92 1.51 110.30 6.28
Splicing factor 45 36.91 0.00020387 RBM17 4.99 1.20 44.93 5.97
ATP-dependent DNA helicase Q1 47.07 1.9619E-05 RECQL 2.47 -1.46 73.41 7.88
ribonuclease H2 subunit B isoform 2 30.81 0.000829851 RNASEH2B 8.17 -1.39 28.99 8.82
Ribonuclease P protein subunit p14 68.05 1.56675E-07 RPP14 16.13 -1.29 13.68 7.75
Ribonuclease P protein subunit p38 74.83 3.28852E-08 RPP38 6.36 -1.32 31.81 9.92
splicing factor 3A subunit 1 isoform 2 117.45 1.79925E-12 SF3A1 7.01 1.21 81.63 5.34
Nuclear receptor coactivator NC0A-62 31.32 0.000737904 SNW1 2.67 1.20 43.31 9.70
Splicing regulatory glutamine/lysine-rich protein 1 56.27 2.36048E-06 SREK1 1.97 1.21 59.35 10.39
Serine/arginine repetitive matrix protein 1 78.24 1.49833E-08 SRRM1 8.19 -1.24 102.27 11.84
Splicing factor arginine/serine-rich 11 25.87 0.002588213 SRSF11 6.25 1.34 13.13 6.28
Splicing factor, arginine/serine-rich 5 120.94 8.056E-13 SRSF5 25.81 -1.37 14.43 10.08
Transcription elongation factor A protein 1 91.04 7.86502E-10 TCEA1 17.28 1.29 33.95 8.38
EKC/KEOPS complex subunit TPRKB 78.14 1.53358E-08 TPRKB 12.68 -1.31 16.08 6.30
tRNA (guanine-N(1)-)-methyltransferase 46.82 2.0797E-05 TRMT5 2.95 1.33 58.21 8.62
Exportin-5 28.18 0.001521507 XPO5 12.21 -1.20 136.22 5.80
zinc finger, CCHC domain containing 8 72.69 5.3827E-08 ZCCHC8 12.28 -1.52 18.10 4.65
zinc finger protein 2 (Fragment) 27.62 0.001729816 ZNF2 0.83 1.43 118.55 6.43
Zinc finger protein 511 59.64 1.08643E-06 ZNF511 5.56 -1.51 28.25 7.66
*Zinc finger SWIM domain-containing protein 5 15.31 0.029444216 ZSWIM5 0.59 -2.63 130.55 7.18
dolichyl-diphosphooligosaccharide—protein glycosyltransferase subunit
2 isoform 2 precursor
35.79 0.000263633 RPN2 15.77 1.22 67.68 6.06
IMMUNE RESPONSE
Beta-defensin 119 25.85 0.002601985 DEFB119 7.14 -1.92 9.81 8.57
F-box/LRR-repeat protein 8 27.08 0.001958845 FBXL8 6.2 1.53 14.20 6.99
Guanine nucleotide-binding protein-like 1 74.73 3.36284E-08 GNL1 4.2 1.80 28.69 4.69
HLA class II histocompatibility antigen, DQB1*0602 beta chain 25.92 0.002558586 HLA-DQB1 5.88 1.31 15.76 8.85
Interferon regulatory factor 7 203.30 4.67539E-21 IRF7 4.53 1.48 42.25 5.34
Dual specificity mitogen-activated protein kinase kinase 3 38.59 0.000138357 MAP2K3 5.66 1.33 36.15 6.25
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Macrophage-expressed gene 1 protein 49.94 1.01391E-05 MPEG1 0.84 1.49 78.54 7.65
*G antigen family B member 1 116.72 2.13016E-12 PAGE1 19.86 -1.53 16.14 4.22
*Phosphoinositide 3-kinase regulatory subunit 4 24.48 0.003564511 PIK3R4 0.44 1.46 153.01 7.17
Pirin 158.71 1.3466E-16 PIR 7.24 1.31 32.09 6.92
Parathymosin 230.82 8.27378E-24 PTMS 22.55 1.44 11.52 4.16
SAM domain and HD domain-containing protein 1 60.21 9.52153E-07 SAMHD1 6.15 -1.49 69.40 7.20
single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 81.02 7.90679E-09 SIGIRR 11.97 -1.33 15.50 4.86
Serine/threonine-protein kinase TBK1 60.83 8.26038E-07 TBK1 2.74 -1.39 83.59 6.79
Zinc finger CCCH-type antiviral protein 1 86.04 2.48886E-09 ZC3HAV1 3.58 -1.20 77.85 8.38
METABOLISM
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial 112.09 6.18431E-12 AADAT 12.12 1.24 47.79 7.21
Abhydrolase domain-containing protein 10, mitochondrial 35.49 0.000282488 ABHD10 13.73 1.23 33.91 8.57
acyl-CoA thioesterase 9 49.12 1.22462E-05 ACOT9 9.56 -1.31 15.45 8.59
Adenylate kinase isoenzyme 1 250.33 9.27582E-26 AK1 27.84 -1.20 21.62 8.63
GTP:AMP phosphotransferase, mitochondrial isoform c 91.18 7.61682E-10 AK3 22.93 1.29 18.18 8.78
Argininosuccinate synthase 548.15 1.52978E-55 ASS1 26.22 -1.35 50.79 8.40
ATP synthase subunit beta, mitochondrial 6847.36 0 ATP5B 72.78 1.20 56.52 5.40
ATP synthase gamma chain 89.04 1.24654E-09 ATP5C1 8.8 1.32 27.50 7.42
ATP synthase subunit epsilon-like protein, mitochondrial 32.85 0.0005188 ATP5EP2 13.73 1.31 5.80 10.14
ATP synthase subunit b, mitochondrial 198.92 1.28165E-20 ATP5F1 11.72 1.36 28.89 9.36
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1
(Subunit 9)
247.94 1.60823E-25 ATP5G1 7.07 2.35 10.19 10.40
ATP synthase-coupling factor 6, mitochondrial 78.67 1.35831E-08 ATP5J 17.59 1.24 12.58 9.52
ATP synthase subunit f, mitochondrial isoform 2d 42.39 5.76766E-05 ATP5J2 59.18 1.59 5.74 9.70
ATP synthase subunit g, mitochondrial 88.08 1.55639E-09 ATP5L 28.95 1.20 8.45 10.29
ATP synthase subunit O, mitochondrial 607.69 1.70258E-61 ATP5O 38.97 1.22 23.26 9.96
ATP synthase mitochondrial F1 complexassembly factor 2, mitochondrial 42.39 5.76766E-05 ATPAF2 21.19 -1.24 13.05 9.51
ADP-ribosyl cyclase 2 49.30 1.17453E-05 BST1 1.89 1.21 35.70 7.80
citrate lyase beta like (CLYBL), transcript variant 2, mRNA 25.67 0.002710192 CLYBL 1.99 1.43 32.83 8.29
Coatomer subunit gamma-2 296.91 2.03587E-30 COPG2 7.23 -1.21 97.56 5.81
Cubilin 26.56 0.002208005 CUBN 0.28 1.26 398.48 5.35
Lanosterol 14-alpha demethylase 31.32 0.000737904 CYP51A1 6.31 1.20 25.63 9.22
Elongation factor 1-alpha 1 2876.54 2.2169E-288 EEF1A1 17.32 1.42 50.12 8.95
Elongation factor 1-gamma 847.83 1.6494E-85 EEF1G 39.13 1.24 50.09 6.67
Eukaryotic translation initiation factor 3 subunit H 219.98 1.0051E-22 EIF3H 12.78 1.29 39.91 6.54
Eukaryotic translation initiation factor 3 subunit K 146.26 2.36701E-15 EIF3K 20.18 1.30 25.04 4.93
eukaryotic translation initiation factor 4A2 236.48 2.24941E-24 EIF4A2 40.61 -1.70 41.26 5.64
Eukaryotic translation initiation factor 5 355.38 2.89998E-36 EIF5 20.88 1.27 49.19 5.58
Mitochondrial enolase superfamily member 1 31.06 0.00078343 ENOSF1 4.29 -1.21 49.75 6.48
Squalene synthase 308.02 1.57875E-31 FDFT1 19.27 1.28 47.25 6.54
Fibronectin 84.30 3.71838E-09 FN1 1.38 -1.75 222.84 5.68
fibronectin 1 (FN1), transcript variant 5, mRNA 84.30 3.71838E-09 FN1 2.96 -1.32 111.23 6.21
Galactokinase 65.27 2.97119E-07 GALK1 10.71 1.61 42.25 6.46
N-acetylgalactosamine kinase 33.04 0.000496592 GALK2 4.15 1.39 47.60 6.19
FAD-linked sulfhydryl oxidase ALR 73.98 3.99945E-08 GFER 12.2 1.27 23.43 7.62
Glutathione S-transferase 109.04 1.24616E-11 GSTA3 12.21 -1.22 19.73 9.16
Glutathione S-transferase Mu 3 1530.92 8.0923E-154 GSTM3 56.44 -1.24 26.54 5.54
Hydroxyacylglutathione hydrolase, mitochondrial 32.51 0.000561048 HAGH 8.08 -1.26 28.84 7.33
Histone acetyltransferase type B catalytic subunit 134.87 3.25617E-14 HAT1 5.39 -1.40 39.76 5.92
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Isopentenyl-diphosphate Delta-isomerase 1 75.33 2.93089E-08 IDI1 15.86 1.24 26.30 6.34
inositol-tetrakisphosphate 1-kinase 28.46 0.001425608 ITPK1 12.5 -1.58 19.45 6.39
L-lactate dehydrogenase A-like 6A 362.00 6.31588E-37 LDHAL6A 7.23 -1.28 36.48 6.99
Phospholysine phosphohistidine inorganic pyrophosphate phosphatase 113.45 4.51551E-12 LHPP 7.78 -1.23 29.15 6.15
lanosterol synthase isoform 3 54.26 3.7465E-06 LSS 3.07 1.49 74.17 6.46
Leukotriene A-4 hydrolase 45.87 2.58821E-05 LTA4H 2.36 1.46 57.26 6.06
LYR motif-containing protein 7 56.05 2.48146E-06 LYRM7 15.38 1.68 11.95 9.66
NADP-dependent malic enzyme 1228.39 1.4492E-123 ME1 20.98 1.40 64.11 6.13
NAD-dependent malic enzyme, mitochondrial isoform 2 precursor 53.87 4.10204E-06 ME2 5.01 1.52 53.55 8.54
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial 155.89 2.57529E-16 MMAB 28.4 1.31 27.37 8.60
Mannose-6-phosphate isomerase 289.43 1.1405E-29 MPI 18.68 -1.28 46.63 5.95
39S ribosomal protein L53, mitochondrial 45.67 2.70836E-05 MRPL53 13.39 1.65 12.10 8.76
Arylamine N-acetyltransferase 1 68.56 1.39222E-07 NAT1 5.86 -1.28 33.88 6.54
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 35.89 0.000257632 NDUFS1 3.27 1.61 66.88 5.38
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 34.69 0.000339625 NDUFS3 19.23 1.77 8.60 8.03
nitric oxide synthase interacting protein (NOSIP), mRNA 26.13 0.002437811 NOSIP 6.63 -1.81 17.93 8.00
nucleoporin 133kDa 169.20 1.2026E-17 NUP133 7.19 -1.26 120.30 5.15
Nuclear pore complex protein Nup205 41.85 6.53131E-05 NUP205 2.83 -1.40 227.78 6.19
Nuclear pore complex protein Nup93 25.65 0.002722701 NUP93 1.15 -1.25 79.83 6.18
nucleoporin 98kDa 447.74 1.68228E-45 NUP98 6.9 -1.53 26.86 7.39
propionyl-CoA carboxylase alpha chain, mitochondrial isoform c
precursor
24.30 0.003715352 PCCA 1.03 1.46 74.95 7.36
phosphoacetylglucosamine mutase isoform 3 113.80 4.17131E-12 PGM3 8.03 1.33 51.05 5.88
Arfaptin-2 31.82 0.000657658 POR 16.99 1.20 47.37 7.81
Lipid phosphate phosphohydrolase 1 29.39 0.0011508 PPAP2A 7.04 1.22 32.14 7.97
Palmitoyl-protein thioesterase 1 126.47 2.25388E-13 PPT1 9.48 -1.34 34.17 6.52
glucosidase 2 subunit beta isoform 2 450.79 8.33915E-46 PRKCSH 20.19 1.28 59.14 4.42
Prosaposin 1508.14 1.5356E-151 PSAP 21.76 -1.33 58.07 5.17
Ran GTPase activating protein 1 115.42 2.87351E-12 RANGAP1 9.02 -1.35 57.74 4.53
rap1 GTPase-GDP dissociation stimulator 1 isoform 6 90.06 9.85348E-10 RAP1GDS1 11.82 -1.20 56.50 5.44
60S acidic ribosomal protein P2 1310.74 8.4427E-132 RPLP2 70.43 -1.29 11.66 4.54
SUMO-activating enzyme subunit 1 481.73 6.71984E-49 SAE1 18.79 -1.25 38.43 5.30
Sec1 family domain-containing protein 1 72.62 5.47514E-08 SCFD1 6.13 1.24 51.51 6.96
Succinate dehydrogenase [ubiquinone] flavoprotein subunit,
mitochondrial
344.95 3.19778E-35 SDHA 9.61 1.26 63.53 7.24
Protein transport protein Sec24B 38.99 0.000126098 SEC24B 0.89 -1.48 133.54 7.39
serine hydroxymethyltransferase, mitochondrial isoform 3 1864.72 3.3762E-187 SHMT2 49.28 1.24 53.42 8.15
Monocarboxylate transporter 1 106.48 2.24967E-11 SLC16A1 10.42 -1.29 51.80 8.50
Tricarboxylate transport protein, mitochondrial 73.34 4.63657E-08 SLC25A1 7.4 1.20 33.99 9.89
Calcium-binding mitochondrial carrier protein Aralar2 64.84 3.27874E-07 SLC25A13 8.11 1.21 62.21 9.01
solute carrier organic anion transporter family member 1C1 isoform 3 30.95 0.000803526 SLCO1C1 0.9 1.52 73.22 8.85
Translocon-associated protein subunit alpha 271.19 7.59987E-28 SSR1 8.88 1.25 29.36 4.61
Translocon-associated protein subunit delta 141.51 7.06092E-15 SSR4 17.5 1.40 13.06 7.50
UDP-N-acetylhexosamine pyrophosphorylase 80.69 8.52774E-09 UAP1 2.97 1.23 56.99 6.38
UTP—glucose-1-phosphate uridylyltransferase 25.07 0.003111716 UGP2 4.02 1.23 55.64 7.88
Cytochrome b-c1 complex subunit 9 57.97 1.5948E-06 UQCR10 38.1 1.31 7.30 9.47
Cytochrome b-c1 complex subunit 7 94.76 3.34256E-10 UQCRB 21.62 1.22 13.52 8.78
OXIDATIVE STRESS
Cytoplasmic aconitate hydratase 179.53 1.11364E-18 ACO1 6.97 -1.36 98.34 6.68
(Continued)
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*Retinal dehydrogenase 1 385.17 3.03767E-39 ALDH1A1 17.95 1.32 42.57 5.80
*Fatty aldehyde dehydrogenase 262.18 6.06001E-27 ALDH3A2 12.99 1.23 54.81 7.88
Alkylated repair protein alkB 78.29 1.48152E-08 ALKBH5 5.48 -1.41 43.02 9.16
aspartyl/asparaginyl beta-hydroxylase isoform f 131.03 7.88327E-14 ASPH 4.39 2.23 83.22 4.92
Cytochrome b561 86.52 2.22693E-09 CYB561 4.38 1.45 27.54 8.56
Cytochrome b5 126.09 2.45962E-13 CYB5A 42.86 -1.22 11.26 5.14
*Dehydrogenase/reductase SDR family member 1 67.71 1.69434E-07 DHRS1 6.07 1.31 33.89 7.83
Glycine N-methyltransferase 39.20 0.000120226 GNMT 2.71 -1.25 32.72 7.02
MOSC domain-containing protein 1, mitochondrial 40.11 9.7499E-05 MARC1 13.89 -1.23 28.42 7.31
3-mercaptopyruvate sulfurtransferase 72.72 5.34203E-08 MPST 14.48 1.23 33.16 6.60
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase,
mitochondrial
33.26 0.000472063 MTHFD2 5.41 2.00 23.85 9.76
Myb-binding protein 1A 64.54 3.5156E-07 MYBBP1A 0.83 -1.29 148.76 9.28
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial 40.43 9.05733E-05 NDUFS8 8.18 1.86 12.40 9.98
*NAD(P)H dehydrogenase, quinone 1 (NQO1), transcript variant 3,
mRNA
513.20 4.78822E-52 NQO1 52.48 1.28 22.78 8.50
Prolyl 4-hydroxylase subunit alpha-2 36.08 0.000246604 P4HA2 2.25 1.41 60.59 5.71
Protoporphyrinogen oxidase 87.40 1.8197E-09 PPOX 6.98 1.26 46.81 7.31
Pyrroline-5-carboxylate reductase 2 93.93 4.04761E-10 PYCR2 9.38 1.23 33.62 7.77
Retinol dehydrogenase 14 64.68 3.40408E-07 RDH14 7.14 1.44 36.84 8.79
*Sideroflexin-1 318.98 1.26412E-32 SFXN1 32.61 1.21 35.60 9.07
*STEAP family member 2, metalloreductase 90.06 9.86169E-10 STEAP2 6.7 -1.47 45.95 8.91
PROTEOLYTIC
ADAM metallopeptidase domain 9 26.77 0.002103778 ADAM9 3.82 -1.34 69.28 6.65
asparagine synthetase [glutamine-hydrolyzing] isoform b 2335.19 3.0244E-234 ASNS 38.89 1.31 62.13 7.06
Cyclin-dependent kinase 1 29.04 0.001247384 CDK1 8.33 -1.57 27.49 7.06
*Collagen type IV alpha-3-binding protein 48.53 1.40281E-05 COL4A3BP 1.67 -1.40 67.96 5.47
Cystatin-B 190.50 8.90894E-20 CSTB 24.49 -1.82 11.13 7.56
Farnesyl pyrophosphate synthetase like-4 protein (Fragment) 70.77 8.36775E-08 FDPS 8.62 -3.10 39.63 4.98
PSMA’ of Glutamate carboxypeptidase 2 414.93 3.21326E-42 FOLH1 9.24 -1.46 77.95 6.67
Glucosamine—fructose-6-phosphate aminotransferase [isomerizing] 2 148.17 1.52319E-15 GFPT2 6.6 -1.87 76.88 7.37
Minor histocompatibility antigen H13 60.58 8.74071E-07 HM13 6.57 1.21 36.79 6.68
*Hypoxia up-regulated protein 1 2096.90 2.0428E-210 HYOU1 28.53 1.21 111.27 5.22
Leucyl-cystinyl aminopeptidase 91.92 6.43211E-10 LNPEP 2.78 -1.26 114.99 5.78
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 29.41 0.001145513 MALT1 1.97 -1.47 91.02 5.91
E3 ubiquitin-protein ligase MARCH5 27.45 0.001798871 MARCH5 3.6 1.69 31.21 8.70
Neprilysin 670.63 8.64906E-68 MME 20 -1.33 85.46 5.73
neural precursor cell expressed, developmentally down-regulated 8 101.64 6.8544E-11 NEDD8 40 -1.34 5.86 6.70
aminopeptidase NPEPL1 isoform 3 158.36 1.45823E-16 NPEPL1 4.84 -1.22 50.50 6.52
Ubiquitin thioesterase OTUB2 229.61 1.09388E-23 OTUB2 7.02 2.11 12.93 9.29
*OTU domain-containing protein 6B 102.58 5.52077E-11 OTUD6B 14.58 -1.37 21.79 5.10
Proteasome subunit beta type-6 117.00 1.9941E-12 PSMB6 25.1 1.20 25.34 4.92
E3 ubiquitin/ISG15 ligase TRIM25 166.22 2.38646E-17 TRIM25 7.14 -1.22 70.93 8.09
Transcription intermediary factor 1-beta 62.59 5.50752E-07 TRIM28 33.05 -1.23 88.49 5.77
*Ubiquitin-conjugating enzyme E2 variant 2 369.35 1.16185E-37 UBE2V2 60.61 1.56 11.27 5.52
E3 ubiquitin-protein ligase UBR2 39.23 0.000119399 UBR2 4 -1.27 66.01 7.42
Deubiquitinating protein VCIP135 30.73 0.000845279 VCPIP1 0.57 -1.73 134.24 7.20
X-prolyl aminopeptidase (Aminopeptidase P) 1, soluble 38.35 0.000146218 XPNPEP1 3.26 1.41 62.10 5.73
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MSKE Promotes ER Stress Response
PLOS ONE | DOI:10.1371/journal.pone.0164115 October 18, 2016 14 / 26
Table 1. (Continued)







Armadillo repeat containing 2 36.31 0.000233884 ARMC2 9.41 2.12 9.41 6.92
UPF0556 protein C19orf10 33.48 0.000448745 C19orf10 13.87 1.27 18.78 6.68
CDGSH iron-sulfur domain-containing protein 3, mitochondrial 34.93 0.000321366 CISD3 10.24 1.24 14.21 10.55
Protein FAM136A 28.08 0.001555966 FAM136A 6.52 1.30 15.63 7.61
hematological and neurological expressed 1 60.68 8.55067E-07 HN1 9.35 -1.34 11.62 8.47
kelch-like protein 35 27.78 0.001667247 KLHL35 1.2 -1.35 62.85 7.83
Leucine-rich repeat-containing protein 47 55.50 2.81838E-06 LRRC47 2.57 1.43 63.43 8.28
Nucleoside diphosphate-linked moiety X motif 22 1000.35 9.2264E-101 NUDT22 2.12 1.51 30.57 11.56
Regulator of G-protein signaling 10 36.15 0.000242661 RGS10 10.18 -1.31 19.60 5.87
Selenoprotein M 28.07 0.001559553 SELM 9.66 -1.34 16.17 5.54
Serine/threonine-protein phosphatase 4 regulatory subunit 3A 76.44 2.27171E-08 SMEK1 3.15 -1.21 61.98 4.81
Protein kish-A 37.02 0.000198609 TMEM167A 12.5 1.28 8.05 8.95
Transmembrane protein 205 34.49 0.000355631 TMEM205 8.99 -1.37 21.18 8.62
Transmembrane protein 238 42.68 5.39511E-05 TMEM238 10.23 1.40 18.03 11.53
Transmembrane protein 87A 55.86 2.59243E-06 TMEM87A 9.11 -1.33 56.74 5.69
182 kDa tankyrase-1-binding protein 106.18 2.40763E-11 TNKS1BP1 2.6 -1.46 181.69 4.86
UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 31.60 0.000691831 UAP1L1 1.38 -1.24 56.99 6.32
zinc finger CCCH-type containing 18 65.78 2.64005E-07 ZC3H18 5.42 -1.87 39.04 4.89
Leucine-rich repeat-containing protein 59 503.47 4.49936E-51 LRRC59 20.52 1.22 34.91 9.57
rRNA 2’-O-methyltransferase fibrillarin 180.12 9.71673E-19 FBL 11.53 -1.33 33.76 10.18
Clustered mitochondria protein homolog 54.60 3.46545E-06 CLUH 2.14 1.20 146.58 6.13
ATP-dependent RNA helicase DDX31 282.98 5.03956E-29 DDX31 0.97 1.24 80.89 9.83
Neurobeachin-like protein 2 23.89 0.004083194 NBEAL2 0.43 1.66 282.68 6.54
NHP2 ribonucleoprotein 351.04 7.86182E-36 NHP2 33.33 -1.22 15.01 9.25
WD repeat protein 55 59.96 1.00925E-06 WDR55 21.74 -1.43 12.54 6.74
Nucleobindin-2 526.89 2.04772E-53 NUCB2 27.86 1.24 50.16 5.12
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-1 49.48 1.12644E-05 PLCH1 0.8 1.38 114.43 7.64
Ankyrin repeat domain-containing protein 5 84.77 3.3358E-09 ANKEF1 1.42 1.33 86.61 8.28
Calmodulin 383.67 4.29621E-39 CALM 38.26 -1.40 16.83 4.22
Calcyclin-binding protein 64.99 3.17122E-07 CACYBP 13.16 1.30 26.19 8.25
calcium/calmodulin-dependent protein kinase kinase 2, beta 41.30 7.42096E-05 CAMKK2 6.41 -1.48 38.59 6.30
Calmodulin-regulated spectrin-associated protein 3 25.23 0.002999163 CAMSAP3 0.48 1.56 134.67 8.35
Calnexin 1219.69 1.0747E-122 CANX 23.14 1.21 67.53 4.60
Calcium-regulated heat stable protein 1 181.64 6.85365E-19 CARHSP1 10.88 -1.46 15.88 8.21
S-adenosylmethionine synthase isoform type-2 22.48 0.00564937 MAT2A 3.98 1.62 19.46 9.10
40S ribosomal protein S28 416.48 2.24773E-42 RPS28 30.43 1.65 7.84 10.70
*Tetraspanin 48.28 1.48594E-05 TSPAN13 6.29 -2.11 17.75 6.29
Desmoglein-2 112.81 5.23745E-12 DSG2 7.6 1.23 122.22 5.24
Integrin alpha-10 26.55 0.002213095 ITGA10 0.78 1.26 112.47 6.68
Liprin-alpha-1 36.20 0.000239776 PPFIA1 1.6 -1.26 133.89 6.25
WD repeat-containing protein 61 46.62 2.17624E-05 WDR61 6.56 -1.20 33.56 5.47
Syntaxin-12 84.27 3.74231E-09 STX12 6.88 1.63 31.62 5.59
*Dihydropyrimidinase-related protein 5 31.72 0.00067262 DPYSL5 3.68 1.67 20.85 6.42
PDZ domain-containing protein GIPC1 isoform 2 33.42 0.000454988 GIPC1 7.2 -1.30 26.06 5.57
Crk-II of Adapter molecule crk 168.48 1.41897E-17 CRK 7.57 1.26 33.81 5.55
Transducin-like enhancer protein 3 30.90 0.000812831 TLE3 2.11 -1.45 82.17 7.20
Platelet-activating factor acetylhydrolase IB subunit gamma 113.69 4.27563E-12 PAFAH1B3 21.65 1.34 25.72 6.84
(Continued)
MSKE Promotes ER Stress Response
PLOS ONE | DOI:10.1371/journal.pone.0164115 October 18, 2016 15 / 26
Table 1. (Continued)






Histone H3.3 828.78 1.32475E-83 H3F3A 44.85 1.29 15.32 11.27
Histone H1.5 536.77 2.10286E-54 HIST1H1B 21.24 2.49 22.57 10.92
Histone H1.2 1007.80 1.6588E-101 HIST1H1C 30.99 2.29 21.35 10.93
Histone H1.4 1069.83 1.0408E-107 HIST1H1E 30.59 2.89 21.85 11.03
Histone H2B type 1-C/E/F/G/I 1342.18 6.0583E-135 HIST1H2BC 62.7 1.84 13.90 10.32
Histone H3.1 1117.98 1.5924E-112 HIST1H3A 44.85 1.54 15.39 11.12
Histone H4 1317.99 1.5896E-132 HIST1H4A 52.43 1.85 11.36 11.36
Histone H2A type 2-C 969.32 1.16911E-97 HIST2H2AC 55.04 1.97 13.98 10.90
Histone H2B type 2-E 1489.58 1.1021E-149 HIST2H2BE 62.7 1.86 13.91 10.32
Histone H3.2 1363.47 4.4975E-137 HIST2H3A 44.85 1.82 15.38 11.27
Histone H2A.x 516.44 2.27136E-52 H2AFX 59.44 1.22 15.14 10.74
replication factor C subunit 5 isoform 4 34.07 0.000391742 RFC5 2.67 2.24 38.14 7.80
small ubiquitin-related modifier 2 isoform b precursor 154.56 3.50042E-16 SUMO2 16.9 -1.39 8.11 5.41
deoxyuridine 5’-triphosphate nucleotidohydrolase, mitochondrial
isoform 3
160.14 9.68456E-17 DUT 21.99 1.20 15.39 6.57
Single-stranded DNA-binding protein, mitochondrial 882.96 5.06197E-89 SSBP1 53.38 1.22 17.25 9.60
WD repeat-containing protein 72 21.02 0.007906786 WDR72 0.54 1.73 123.35 6.67
Alpha-2-HS-glycoprotein 51.23 7.53356E-06 AHSG 4.9 2.19 27.34 6.52
Stonin-2 37.61 0.00017338 STON2 0.99 1.21 101.10 5.39
protein arginine methyltransferase 1 278.12 1.54264E-28 PRMT1 34.46 -1.37 37.68 6.15
Proline-, glutamic acid- and leucine-rich protein 1 29.98 0.001004616 PELP1 2.02 2.20 110.02 4.30
TBC1 domain family member 10B 32.11 0.000615177 TBC1D10B 0.87 -2.10 87.14 9.19
Nuclear ubiquitous casein and cyclin-dependent kinases substrate 204.85 3.27022E-21 NUCKS1 11.52 -1.23 27.28 5.08
SLD5 homolog (SLD5), mRNA 72.76 5.29663E-08 GINS4 12.84 2.13 12.05 5.74
Microsomal triglyceride transfer protein large subunit 39.58 0.000110154 MTTP 1.23 1.98 99.29 8.41
Protein FAM87A 23.60 0.004365158 FAM87A 4.9 -1.43 31.72 10.01
39S ribosomal protein L2, mitochondrial 47.97 1.5948E-05 MRPL2 2.62 1.22 33.28 11.30
39S ribosomal protein L21, mitochondrial isoform a 51.24 7.51623E-06 MRPL21 15.83 -1.20 13.74 10.07
Serpin B6 108.58 1.38613E-11 SERPINB6 11.49 -1.21 46.34 5.76
Vomeronasal type-1 receptor 5 23.95 0.00402717 VN1R5 1.96 -1.59 40.75 9.20
cilia and flagella associated protein 58 44.44 3.59536E-05 CFAP58 6.52 1.99 11.03 9.23
Membrane-associated progesterone receptor component 1 156.79 2.09251E-16 PGRMC1 22.05 1.29 21.66 4.70
FK506 binding protein12 205.15 3.05816E-21 FKBP1A 35.14 -1.37 3.96 5.78
Peptidyl-prolyl cis-trans isomerase B 548.34 1.4649E-55 PPIB 46.3 1.24 23.73 9.41
selenide, water dikinase 1 isoform 3 221.26 7.4799E-23 SEPHS1 16.2 1.24 35.46 5.21
Probable Xaa-Pro aminopeptidase 3 91.64 6.86257E-10 XPNPEP3 10.98 1.45 48.08 5.62
mitochondrial ribosomal protein L38 (MRPL38) 34.00 0.000398107 MRPL38 3.57 1.22 22.96 6.14
39S ribosomal protein L4, mitochondrial 52.08 6.19534E-06 MRPL4 15.21 -1.20 29.48 10.13
MRPL43 protein (Fragment) 88.64 1.36673E-09 MRPL43 8.97 1.23 15.95 8.66
60S ribosomal protein L32 68.10 1.54882E-07 RPL32 12.78 1.23 15.61 11.44
proteasome assembly chaperone 4 isoform c 50.67 8.57038E-06 PSMG4 24.04 -1.23 11.21 6.51
N-terminal Xaa-Pro-Lys N-methyltransferase 1 149.45 1.13471E-15 NTMT1 11.61 -1.99 25.46 5.52
STE20/SPS1-related proline-alanine-rich protein kinase 800.51 8.88891E-81 STK39 13.35 -1.24 59.60 6.29
toll interacting protein 62.64 5.44503E-07 TOLLIP 17.5 -1.27 8.65 8.35
SUMO-conjugating enzyme UBC9 186.06 2.47947E-19 UBE2I 34.18 -1.27 18.00 8.66
Putative NOL1/NOP2/Sun domain family member 5B 53.31 4.66317E-06 NSUN5P1 7.14 -1.70 16.47 9.26
THO complex subunit 2 40.48 8.95365E-05 THOC2 1.06 1.23 97.21 6.51
ATP-dependent RNA helicase DHX29 65.43 2.86418E-07 DHX29 0.73 1.28 155.14 8.09
Neuron-specific calcium-binding protein hippocalcin 79.07 1.23796E-08 HPCA 6.22 1.63 22.41 4.97
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LC3B in MSKE plus chloroquine co-treatments, which indicates that chloroquine prevents
fusion of autophagosomes to lysosomes, and thus causes an accumulation of autophagosomes
(Fig 3C). Similarly, western blot analysis showed increased LC3BII expression in MSKE plus
chloroquine treatments indicating that chloroquine had inhbitiedMSKE-mediated autophagy
and caused accumulation of LC3BII lipidation products (Fig 3D). Of note, we did not observe
increased LC3BII with MSKE treatment alone (Fig 3D), possibly due to high autophagic flux
that can sometimes not be detected unless one includes an autophagy inhibitor as previously
reported [16].
MSKE Promotes Autophagy-Mediated Apoptosis
To confirm that MSKE causes apoptosis, we treated the C4-2 cells with 5, 10, or 20 μg/ml
MSKE and performed a TUNEL assay. Increased TUNEL staining (green) was observedwith
Table 1. (Continued)






Olfactory receptor 5AC2 37.52 0.000177011 OR5AC2 2.27 -1.39 35.28 8.94
A-kinase anchor protein 8 61.79 6.61769E-07 AKAP8 2.89 1.60 76.06 5.15
Myeloid-associated differentiation marker 61.52 7.04693E-07 MYADM 15.65 1.74 15.92 8.65
*NF-kappa-B-activating protein 26.49 0.002243882 NKAP 1.45 1.65 47.11 10.11
*ATP-binding cassette sub-family A member 5 30.05 0.000988553 ABCA5 0.86 -5.84 104.30 7.12
AP-1 complex subunit mu-2 47.21 1.90108E-05 AP1M2 4.02 -1.53 48.08 8.22
AP-2 complex subunit mu-1 44.57 3.49424E-05 AP2M1 8.27 -1.20 42.67 9.39
ADP-ribosylation factor 5 967.37 1.83259E-97 ARF5 56.11 1.23 20.52 6.79
ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin
A-inhibited)
440.40 9.12033E-45 ARFGEF1 3.27 -1.23 142.44 6.13
ARFAPTIN 1 175.92 2.55929E-18 ARFIP1 17.14 1.25 28.40 7.72
Cellular nucleic acid-binding protein 117.58 1.74464E-12 CNBP 8.82 -1.62 18.73 7.71
Metal transporter CNNM3 22.85 0.005188 CNNM3 0.91 1.22 70.59 7.12
Protein CWC15 homolog 66.10 2.45471E-07 CWC15 4.8 -1.30 26.61 5.71
Acyl-CoA-binding protein 504.05 3.93581E-51 DBI 50.57 -1.32 10.04 6.57
Golgin subfamily A member 5 27.96 0.001599558 GOLGA5 9.4 1.32 12.84 6.04
Hook homolog 1 35.65 0.00027227 HOOK1 2.33 -1.28 79.97 5.19
UPF0459 protein C19orf50 24.35 0.003672823 KXD1 5.11 -1.64 19.66 4.89
LPS-responsive vesicle trafficking, beach and anchor containing 123.34 4.63532E-13 LRBA 1.75 -1.37 286.79 5.52
28S ribosomal protein S16, mitochondrial 56.67 2.15278E-06 MRPS16 9.49 1.38 15.34 9.50
28S ribosomal protein S17, mitochondrial 80.19 9.5737E-09 MRPS17 15.38 1.30 14.49 9.85
28S ribosomal protein S18b, mitochondrial 93.79 4.17548E-10 MRPS18B 7.91 1.50 24.34 8.56
myosin, light chain 6, alkali, smooth muscle and non-muscle 497.53 1.76602E-50 MYL6 46.67 -1.25 15.01 5.00
Myosin-Id 149.00 1.25876E-15 MYO1D 2.49 -1.30 116.13 9.39
Ran-binding protein 6 46.97 2.00815E-05 RANBP6 2.44 -1.25 124.63 5.01
Ammonium transporter Rh type B 28.58 0.001386756 RHBG 11.34 1.28 10.57 8.76
Secretory carrier-associated membrane protein 2 135.77 2.64671E-14 SCAMP2 3.95 1.68 36.63 6.10
Mitochondrial glutamate carrier 1 84.11 3.8815E-09 SLC25A22 4.64 1.21 34.45 9.29
ADP/ATP translocase 2 1271.34 7.3482E-128 SLC25A5 47.65 1.24 32.83 9.69
spermatogenesis associated 7 29.05 0.001244515 SPATA7 16.67 -1.46 4.76 10.26
Sarcalumenin 23.75 0.004221453 SRL 2.32 -1.71 49.78 6.95
Serine/threonine-protein kinase WNK1 31.00 0.000794328 WNK1 0.71 2.19 206.52 7.15
Note: The asterisk (*) indicates the proteins discussed in the manuscript.
doi:10.1371/journal.pone.0164115.t001
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higher doses of MSKE (Fig 4A). These findings correlate with theWestern blot analysis where
up-regulation of pro-apoptotic markers PARP and caspase-12 was observed (Fig 2). These
results support the hypothesis that MSKE induces apoptosis in C4-2 prostate cancer cells. To
support the findings in the TUNEL assay and show that there was a correlation between autop-
hagy and apoptosis, we performed quantitative apoptosis assay using flow cytometry via the
Alexa Fluor 488 Annexin V in the presence or absence of chloroquine (autophagy inhibitor).
Graphical representation of the apoptosis assay showed that treatment with MSKE led to an
increase of apoptosis which was abrogated by treatment with chloroquine (Fig 4B). Western
blot analysis confirmed these findings by showing that MSKE-mediated increase in pro-apo-
ptotic proteins BAX, cleaved caspase-3 and -7, and decrease in anti-apoptotic protein BCL2
was abrogated by co-treatment with chloroquine (Fig 4C and 4D). Therefore, MSKE-mediated
autophagy leads to apoptosis.
Discussion
We investigated the impact of MSKE on the C4-2 proteome using a quantitative TMT isobaric
labeling approach with subsequent protein identification by mass spectrometry. Changes in
C4-2 cells were also examined by Western blot. Autophagy and apoptosis were determined by
acridine orange, TUNEL/AnnexinV analyses, respectively. The results indicated that MSKE
significantly regulated components of the UPR stress inducing pathways that include chaper-
ones, ER stress antioxidant enzymes, proteolytic enzymes, cytoskeletal proteins, as well as
enzymes involved in autophagy or apoptosis. Autophagy is a dynamic process, whereby cyto-
plasmic proteins and cellular organelles are enveloped in autophagosomes and degraded by
Fig 2. Quantitative Western blot of key ER stress markers. Western blot analysis in C4-2 cells treated with 20 μg/ml MSKE
as compared to ethanol-treated controls. As a loading control total protein from Ponceau S staining was assessed. Expression
of ER stress markers IRE1-alpha and GRP78 and pro-apoptotic markers DFF45, PARP and caspase-12 was analyzed and
quantification of western blot analysis performed using Image J, NIH. The standard deviation was used to assess data
dispersion.
doi:10.1371/journal.pone.0164115.g002
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fusion with lysosomes for amino acid and energy recycling [17]. There is evidence that autop-
hagy can play a critical role in cellular survival [18] but, it is frequently activated in tumor cells
following anticancer therapies such as drug treatment and gamma-irradiation [19]. Apoptosis
is defined as an active, fixed-pathway process of cell death characterized by cell shrinking, cyto-
plasmic condensation, ladder DNA degradation, and nuclear fragmentation resulting in the
formation of apoptotic bodies. Initial studies on the mechanism of action of MSKE, suggest the
ability to induce apoptosis via activation of the caspase cascade. The increase of apoptosis after
MSKE treatment was confirmedwith the TUNEL and Annexin V assays, in agreement with
previous studies that have shown that MSKE promotes apoptosis in prostate cancer cells [7].
Our current study identified several proteins associated with apoptosis triggered by MSKE
treatment such as STEAP2, PDCD6,MTDH, RAB5B, and cytochrome C oxidase (Table 1).
STEAP2, also known as 6-transmembrane protein of the prostate 1 (STAMP1) is overex-
pressed in several types of human cancers, namely prostate, bladder, colon, pancreas, ovary,
testis, breast, and cervix, but its clinical significance and role in cancer cells is still unclear
[20]. STEAP2 participates in a wide range of biological processes, including molecular traf-
ficking in the endocytic and exocytic pathways. It also controls cell proliferation and apopto-
sis. STEAP2 was down-regulated in C4-2 cells. It has been shown that STEAP2 blockage has a
Fig 3. MSKE treatment induces autophagy. (A) C4-2 prostate cancer cells were treated with MSKE (0 μg/mL, 5 μg/mL, 10 μg/mL,
and 20 μg/mL) for 72 h. Fixation was performed with methanol/ethanol 1:1 volume followed by washes with 1× PBS. The cells were then
exposed to acridine orange (5 μg/ml) for 15 min at 37˚C, followed by washes with 1× PBS, prior to counterstaining with DAPI. We
observed that treatment with higher concentrations of MSKE (10 and 20μg/ml) showed extensive acridine orange leakage into the
cytosol, producing a diffuse yellow color and an increase in lysosomes indicating that MSKE induces cell death via autophagy compared
to control. (B) C4-2 cells were treated with MSKE, with and without 20 μM chloroquine, for 72 h. The cells were then exposed to acridine
orange (5 μg/ml) for 15 min at at 37˚C, followed by washes with 1× PBS, prior to counterstaining with DAPI. Chloroquine treatment
reversed the effects of MSKE. (C) Immunofluorescence staining for LC3B was performed on C4-2 cells treated with MSKE plus or minus
chloroquine for 72 h. (D) Western blot analysis for LC3B was performed on C4-2 cells treated with MSKE plus/minus chloroquine. Image
J analysis was performed to plot the ratios of LC3BI and LC3BII relative to actin loading control. The results are representative of
experiments that have been performed in triplicate at least two times independently. Graphical data represents three independent
experiments; * means 0.05 > p value > 0.01, ** means 0.01 > p value > 0.001.
doi:10.1371/journal.pone.0164115.g003
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pro-apoptotic role that causes mitochondrial damage, and decreases cell proliferation and
glucose uptake [20]. MTDH was up-regulated by 1.91 fold uponMSKE treatment in C4-2
cells. MTDH has been proposed to promote tumor progression through the integration of
multiple signaling pathways including ras, myc, Wnt, PI3K/AKT, and NF-κB in various types
of cancer [21–24].
The nuclear protein Apoptotic Chromatin Condensation Inducer 1 (ACIN1) is known to
function in DNA fragmentation and is activated during apoptosis by caspase-3. It also plays an
active role in spliceosome assembly because it is a critical subunit of an apoptosis and splicing-
associated protein (ASAP) complex [25,26]. ACIN1 was down-regulated in our study by -1.60
fold and we speculate that MSKE induced an anti-apoptotic/survival response in C4-2 cells by
down-regulating ACIN1. Taxilin protein (TXLNA), a binding partner of the syntaxin family
that functions as a central player in the intracellular vesicle traffic, and is a marker of testicular
injury [27] was also upregulated uponMSKE treatment.
Several results support the induction of apoptosis by MSKE via autophagy. The acridine
orange staining showed that induced autophagy increasedwith MSKE treatment in a dose-
dependent manner. Additionally, ER stress was significantly induced uponMSKE treatment in
C4-2 cells as seen in the up-regulation of several stress-related proteins (e.g., GRP78, PDIA4,
Fig 4. MSKE induces autophagy-mediated apoptosis. (A) C4-2 prostate cancer cells were treated with increasing concentrations of
0μ g/mL, 5 μg/mL, 10 μg/mL, and 20 μg/mL for 72 h. The cells were fixed with 4% paraformaldehyde and permeabilized with 0.1%
sodium citrate and 0.1% Triton X. DNA fragmentation was determined by TdT-mediated dUTP nick end labeling (TUNEL). TUNEL assay
(green channel). DAPI (blue channel) is used to locate the nuclei of the cells. (B) Cells were stained with Annexin V- Alexa Fluor 488 and
PI and analyzed by flow cytometry following treatment with 5 μg/mL MSKE with or without 20 μM chloroquine. Percent of cells in the
lower right quadrant that represent Annexin V +/PI- or early apoptotis and cells in the upper right quadrant that represent Annexin V +/PI+
or late apoptotis was graphed. (C) Western blot analysis was performed to examine pro-apoptotic markers (Bax, cleaved caspase-3 and
-7) and anti-apoptotic marker (BCL2) following treatment with MSKE in the presence or absence of 20 μM chloroquine. Actin was utilized
as a loading control. (D) Results of western blot were analyzed using Image J and graphed. The experiments were performed in triplicate
at least two times independently. Graphical data represents three independent experiments; * means 0.05 > p value > 0.01, ** means
0.01 > p value > 0.001, and *** means p value < 0.001.
doi:10.1371/journal.pone.0164115.g004
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PDIA6, eIF2B, eIF4EBP1).We also identifiedCOL4A3BP whose down-regulation sensitizes
cancer cells to multiple cytotoxic agents, potentiating ER stress [28]. Lysosomal inhibitors such
as chloroquine that inhibit acidification inside the lysosome or inhibit autophagosome-lyso-
some fusion and can block the degradation of LC3BII, leading to the accumulation of LC3BII,
are good indicators for autophagy [29]. Co-treatment with MSKE plus chloroquine in C4-2
cells increased LC3B punctate staining as shown by immunofluorescence, and increased
LC3-BII expression as shown by western blot analysis, proving that MSKE promotes autophagy
which is blocked by chloroquine leading to accumulation of LC3BII.We speculated, however,
that at 72 h we failed to see increased LC3BII with MSKE treatment alone due to high autopha-
gic flux. This problem that sometimes arises when LC3BII expression does not increase when
assayed at a certain time point as expected due to high autophagic flux is discussed in great
detail with the conclusion that it is better to gauge autophagy by examining autophagosome
accumulation in the presence of chloroquine [16]. We also demonstrated that chloroquine was
able to reverse the extensive acridine orange leakage into the cytosol.
Degradation of cytosolic proteins in lysosomes is a hallmark of autophagy [30]. The absence
of chromatin condensation is another characteristic of autophagy and indicative of apoptosis
[31]. Recent studies have shown that a variety of anticancer therapies (including those that
stimulate ER stress) activate autophagy in tumor cells, which has been proposed to either
enhance cancer cell death or act as a mechanism of resistance to chemotherapy [32]. Autop-
hagy works as a tumor suppression mechanism by removing damaged organelles/proteins, lim-
iting cell growth and minimizing genomic instability [33]. Phosphatidylinositol 4-Kinase
(PI4KA), a protein involved in both nonselective and selective types of autophagy [34], was up-
regulated in MSKE-treated C4-2 cells. The expression of metadherin (MTDH), also known as
astrocyte-elevated gene-1, a protein that may protect normal cells from serum starvation-
induced death through protective autophagy [35], increased 1.91 fold in the presence of MSKE.
In addition, phosphoglycerate kinase (PGK2), a cytosolic and glycolytic marker, was down-
regulated by MSKE in C4-2 cells, suggesting that it may have been taken up into autophagic
bodies [36].
ER stress was evident by the up-regulation of key ER stress markers like GRP78 and PDIA4,
A6. Proper protein folding, maturation, and stabilization of the nascent protein in the ER
requires a highly oxidizing ER environment, which is essential for the diverse post-translational
and co-translational modifications (e.g., glycosylation, disulfide bridge formation) to which
proteins are subjected after entering the ER. These processes are assisted and monitored by sev-
eral resident chaperones and binding proteins, including glucose-regulatedproteins like
GRP78, which was up-regulated in the presence of MSKE. Folding enzymes, such as the thiore-
doxin-like protein (PDI), oxidize cysteine residues in nascent proteins (i.e., oxidative folding)
resulting in the formation of intra- and intermolecular disulfide bonds. MSKE resulted in ER
stress pathway activation and subsequent translation initiation component activation (i.e.,
eIF4EPB, eIF2). Moreover, the upregulation of pro-apoptotic markers MTDH, caspase 12,
Cytochrome C oxidase, PDCD6 and NQO1, along with the increased apoptosis visualized by
TUNEL and Annexin V staining, suggest that the ER stress response might eventually trigger
apoptosis.
Overexpression of MTDH, also known as LYRIC, is observed in a variety of cancers and is
involved in cancer initiation, proliferation, invasion, metastasis and chemoresistance [37].
MTDH also activates the PI3K/Akt pro-apoptotic pathway in cancer [38] and its inhibition
induces apoptosis in prostate cancer cells [39]. Hudson et al. have also shown that treatment
with MSKE activates the PI3K/Akt pro-apoptotic pathway in prostate cancer cells [7].
The upregulation of cytoplasmic C oxidase and Glyoxalase I (GLO1) suggests that MSKE
also interferes with glycolysis and mitochondrial metabolism in C4-2 cells. GLO1 is a
MSKE Promotes ER Stress Response
PLOS ONE | DOI:10.1371/journal.pone.0164115 October 18, 2016 21 / 26
ubiquitous cellular defense enzyme involved in detoxification. GLO1 expression may protect
cells against methylglyoxal-dependent protein adduction and cellular damage associated with
diabetes, cancer, and chronological aging. GLO1 upregulation has been shown to play a pivotal
role in glycolytic adaptations of cancer cells [40]. Phosphoglycerate kinase, a protein encoded
by the PGK1 and PGK2 genes, is a glycolytic protein activated by MSKE. Phosphoglycerate
kinase converts 1,3-diphosphoglycerate into 3-phosphoglycerate in the glycolysis pathway.
PGK1 is located on the X chromosome and is ubiquitously expressed whereas PGK2, whose
differential expression was induced by MSKE in C4-2 cells, is a retrotransposed copy of PGK1
located on chromosome 6 that shows a testis specific expression pattern [41,42]. Our analyses
demonstrated overexpression of HYOU1, CTTN and DPYSL5, and down-regulation of
ABCA5 proteins in C4-2 cells. These proteins have been implicated in other cancer cells and
tumor types and are involved in relevant cell mechanisms for apoptosis evasion, increased
tumor invasiveness, tumor hypoxia, cellular respiration, and mitochondrial fragmentation.
ABCA5 is a member of the ATP-binding cassette transporter 1 subfamily of genes whose
mutations are linked to several human genetic disorders including cystic fibrosis, neurological
disease, retinal degeneration, cholesterol and bile transport defects, anemia, and drug response
phenotypes [43].
MSKE also activates oxidative stress and ROS pathways through aldehyde dehydrogenases
(ALD), sideroflexin, sulfiredoxin and DHRS1. ALDH belongs to a group of NAD(P)+-depen-
dent enzymes involved in oxidation of a large number of aldehydes into their weak carboxylic
acids [44]. ALDH is important for drug resistance, cell proliferation, differentiation, and
response to oxidative stress in prostate cancer and its activity is used to distinguish between
normal cells and their malignant counterparts. In a previous study, high ALDH activity was
used to isolate human prostate cancer cells with significantly enhanced clonogenic and migra-
tory properties both in vitro and in vivo. As seen in other cancer tissues, the percentage of
ALDH cells in prostate cancer cell lines are also related to tumorigenicity and metastatic behav-
ior [45].
MSKE induced apoptosis via the up-regulation of ER stress-driven caspase-3,-7 and -12.
Treatment with chloroquine blocked the effects of MSKE on apoptosis by up-regulating BCL-
2, decreasing BAX, preventing the cleavage of caspase-3 and -7 and antagonizing MSKE-medi-
ated increase in early and late apoptosis. This further supports the findings that MSKE-medi-
ated autophagy leads to apoptosis. MSKE also prompted the down-regulation of anti-apoptotic
and survival proteins like Annexin A4 (ANXA4), a member of the Ca2+-regulated and phos-
pholipid-binding annexin superfamily. ANXA4 expression is increased in many cancer types,
including cancers of renal, gastric, colonic, ovarian, and cervical origins [46–50]. Its expression
has been linked to loss of cell-to-cell adhesion, increasedmetastasis, and chemo-resistance, and
it is considered a potential cancer diagnostic and therapeutic target [51,52]. In vitro studies sug-
gest that ANXA4 exhibits an anti-apoptotic effect by activating NF-κB transcriptional activity
[53,54]. Our data suggests that MSKEmay induce apoptosis by decreasing ANXA4, and
increasingMTDH.
Recently, the cross-talk between autophagy and apoptosis has been considered as a key fac-
tor in the development and treatment of cancer [55]. The two pathways share molecular regu-
lators and, in some cases, are activated by the same stimulus. Taken together, the results of this
study suggest that MSKE induces apoptosis through signaling pathways that modulate ER
stress, autophagy, cytoskeletal changes, cell-matrix, and cell-cell adhesion, as well as glycolysis
and mitochondrial metabolism (Fig 5); opening the door to novel therapeutic and clinical
exploitations.
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Fig 5. Proposed model highlighting unfolded protein response pathway with pro-apoptotic protein
signatures triggered by ER stress in MSKE treated C4-2 prostate cancer cells. MSKE treatment of C4-2
cells promoted an unfolded protein response (UPR) pathway in a mitochondria-specific stress response
(UPRmt) with pro- and anti-apoptotic protein signature triggered by ER stress. Strong ER stress and activation
of the UPR initiate apoptosis. In contrast, mild UPR activation induces a beneficial ER homeotic response by
reducing the load of misfolded proteins and by activating cellular protective mechanisms like autophagy. PERK
mediates phosphorylation of eIF2α and ATF4-dependent transcriptional activation of autophagy proteins. The
model highlights insufficient folding or degradation capacity in the mitochondria, contributing to apoptosis.
doi:10.1371/journal.pone.0164115.g005
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